Formation Bio Eyes Abivax-Like Success with Chinese Drug Licensing Deal Targeting Same Mechanism
No direct news found on Formation Bio licensing a drug from China matching Abivax's target; query may refer to recent trend of major deals like RemeGen's $5.6B agreement with AbbVie for RC148, a PD-1/VEGF bispecific antibody cancer drug (Jan 2026)1.
RemeGen received $650M upfront plus up to $4.95B milestones and royalties from 10-20% on global sales ex-Greater China; AbbVie gains exclusive rights outside China1.
RC148 is in Phase 1/2 trials for lung/breast cancers, promising in combo with ADCs1.
Trend of high-value oncology licensing from Chinese biotechs to global pharmas continues into 2026, driven by innovative bispecifics and ADCs23.
Abivax focuses on immunology (e.g., obefazimod for ulcerative colitis); no confirmed link to Formation Bio or exact target match in results12.
Sources:
1. https://www.caixinglobal.com/2026-01-15/abbvie-bets-big-on-chinese-cancer-drug-in-56-billion-licensing-deal-102403773.html
2. https://www.pharmaceutical-technology.com/features/china-pharma-licensing-deals-oncology-innovative-drugs/